畜牧兽医学报 ›› 2012, Vol. 43 ›› Issue (2): 270-274.doi:

• 预防兽医 • 上一篇    下一篇

猪瘟病毒多表位基因的表达及其免疫原性分析

田宏,侯相民,吴锦艳,陈妍,尚佑军,刘湘涛*   

  1. 中国农业科学院兰州兽医研究所 家畜疫病病原生物学国家重点实验室,兰州 730046
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2012-02-15 发布日期:2012-02-15
  • 通讯作者: 刘湘涛

Expression of Compound Multiepitope Gene of Classical Swine Fever Virus in E. coli and the Assessment of Its Immunologicity

TIAN Hong, HOU Xiangmin, WU Jinyan, CHEN Yan, SHANG Youjun, LIU Xiangtao*   

  1. Key Laboratory of Animal Virology of Ministry of Agriculture, State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Lanzhou 730046, China
  • Received:1900-01-01 Revised:1900-01-01 Online:2012-02-15 Published:2012-02-15
  • Contact: LIU Xiangtao

摘要: 体外表达猪瘟病毒(CFSV)T、B细胞表位,并对表达产物的免疫原性进行分析。人工合成CFSV的多个T、B细胞表位及表位之间的连接linker基因, 并将该基因插入pGEX6P1表达载体,经酶切和测序鉴定获得重组阳性克隆,成功构建了CFSV复合多表位抗原基因的原核表达质粒pGEXBT500,转化E. coli BL21,IPTG诱导表达,纯化表达产物并免疫兔。结果:通过IPTG诱导目的基因可高效表达,SDSPAGE结果表明,以终浓度为0.9 mmol·L-1的IPTG进行诱导,7 h后表达量最高,产物分泌表达,相对分子质量约43 ku,表达产量约占菌体总蛋白的30%。Western blotting检测表明,表达的融合蛋白能与猪瘟阳性血清发生特异性反应;兔攻毒试验表明所免疫表达产物可保护(根据发热反应评价)兔。结果表明表达获得的产物具有良好的反应原性,这为应用该融合蛋白制备CSFV免疫血清学诊断试剂和多表位疫苗研究奠定了基础。

Abstract: Genetical engineer T, B cell epitopes of Classical swine fever virus (CSFV) were developed by employing molecular biological tools, and their immunogenicity has been primarily evaluated by immunizing experimental animals. A DNA fragment which encoding a tandem repeat protein of T, B cell epitopes of CSFV were designed and chemically synthesized, and it was cloned into pGEX6P1 vector in turn to form a recombinant plasmid pGEXBT500. A chimeric protein was obtained after transforming the pGEXBT500 into Escherichia coli BL21 (DE3) host cell and induced by IPTG. The western blotting analysis showed that the expressed products have a good reactogenicity, which can react specially with CSF positive sera. Inoculation with 100 μg recombinant protein induced strong neutralizing antibody response in rabbits. Our study indicated that the expressed T, B epitopes can act as the carrier protein for CSFV peptide epitopes, and this recombinant protein is a potential multiepitope peptide vaccine candidate to prevent CSFV infection.